Sex differences in hepatocellular carcinoma

Abstract

Disparities in the prevalence, progression and prognosis of hepatocellular carcinoma between males and females are well documented, which stem from a complex interplay of various factors. Sex-specific lifestyle, behavioral and psycho-socioeconomic influences, combined with intrinsic hormonal and genetic differences, significantly impact the process of hepatocarcinogenesis. These factors are further augmented by epigenetic mechanisms and co-factors such as hepatitis B and C infections, and metabolic dysfunction-associated steatotic liver disease. Further research is required to elucidate the mechanisms driving these clear sex differences, in order to optimize future prevention and treatment strategies.

Keywords

Hepatocellular carcinoma / sex / metabolic dysfunction-associated steatotic liver disease

References

[1] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[2] Wu EM,Hernandez BY.Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation.Hepatoma Res2018;4:66 PMCID:PMC6347119

[3] Liu Y,Hao J.Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019.Cancer Med2022;11:1310-23 PMCID:PMC8894698

[4] Huang DQ,Kamal R.Antiviral therapy utilization and 10-year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.J Clin Oncol2024;42:790-9

[5] Tan DJH,Ng CH.Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH.Hepatology2023;77:1150-63

[6] Pan C, Attar B, Lo C, Achebe I. S1531 epidemiological trends and gender differences in hepatocellular carcinoma: analysis from the global burden of disease study 2019. Am J Gastroenterol 2023;118:S1161. Available from: https://scholar.google.com/scholar?hl=zh-CN&as_sdt=0%2C5&q=10.14309%2F01.ajg.0000955764.74781.d8&oq=%3A10.14309%2F01.ajg.0000955764.74781.d8. [Last accessed on 3 Dec 2024].

[7] Beudeker BJB,Stoyanova K.Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology.Sci Rep2024;14:4302 PMCID:PMC10881579

[8] Liou WL,Chen K,Chang JP.Gender survival differences in hepatocellular carcinoma: is it all due to adherence to surveillance?.JGH Open2023;7:377-86 PMCID:PMC10230112

[9] Davila JA,Richardson PA,McGlynn KA.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.Hepatology2010;52:132-41 PMCID:PMC3835698

[10] Davis JL,Katz RV.Gender differences in cancer screening beliefs, behaviors, and willingness to participate: implications for health promotion.Am J Mens Health2012;6:211-7 PMCID:PMC3776317

[11] O'Brien R,Hart G.‘It’s caveman stuff, but that is to a certain extent how guys still operate’: men’s accounts of masculinity and help seeking.Soc Sci Med2005;61:503-16

[12] Pelletier R, Humphries KH, Shimony A, et al; GENESIS-PRAXY Investigators. Sex-related differences in access to care among patients with premature acute coronary syndrome. CMAJ 2014;186:497-504. PMCID:PMC3986312

[13] Mauvais-Jarvis F,Barnes PJ.Sex and gender: modifiers of health, disease, and medicine.Lancet2020;396:565-82 PMCID:PMC7440877

[14] Farinati F, Sergio A, Giacomin A, et al; Italian Liver Cancer group. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8.

[15] Shimizu I,Tamaki K.Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.World J Gastroenterol2007;13:4295-305 PMCID:PMC4250853

[16] Zhong GC,Chen N.Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.Hum Reprod Update2016;23:126-38

[17] Li Z,Schug J.Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.Cell2012;148:72-83 PMCID:PMC3266536

[18] Yang JD,Pang H.Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.Hepatology2014;59:1406-14 PMCID:PMC3966932

[19] Tanaka K,Hashizume M.Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients.Cancer Res2000;60:5106-10

[20] Carruba G.Estrogens in hepatocellular carcinoma: friends or foes?.Cancers2021;13:2085 PMCID:PMC9688455

[21] Liang T,Mo S.Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy.Ann Hepatol2022;27:100695

[22] Lam CM,Chan AO.Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related?.J Clin Gastroenterol2005;39:533-9

[23] Chow PK, Tai BC, Tan CK, et al; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:1221-6.

[24] Nevola R,Rosato V.Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma.Biology2023;12:984 PMCID:PMC10376683

[25] Wang SH,Lin WH,Chen DS.Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B.Hepatology2009;50:1392-402

[26] Cherubini A, Ostadreza M, Jamialahmadi O, et al; EPIDEMIC Study Investigators. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med 2023;29:2643-55. PMCID:PMC10579099

[27] Li A,Zhao Y,Yang J.Crosstalk between epigenetics and metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease-induced hepatocellular carcinoma: a new sight.Metabolites2024;14:325 PMCID:PMC11205353

[28] Rongrui L,Zongfang L,Shiwen J.Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis.Curr Pharm Des2014;20:1715-25

[29] Li CL,Lin YY.Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region.Hepatology2019;69:498-512 PMCID:PMC6498540

[30] Ji F,Liu N.Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.Gut2022;71:2313-24

[31] Abboud Y,Khan H.Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades.J Clin Transl Hepatol2024;12:172-81 PMCID:PMC10851066

[32] White AM.Gender differences in the epidemiology of alcohol use and related harms in the United States.Alcohol Res2020;40:01 PMCID:PMC7590834

[33] Lonardo A,Ballestri S.Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps.Hepatology2019;70:1457-69 PMCID:PMC6766425

[34] Lonardo A,Chow PKH.Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms.Hepatoma Res2020;6:83

[35] Piscaglia F, Svegliati-Baroni G, Barchetti A, et al; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.

[36] Ladenheim MR,Nguyen P.Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study.BMJ Open Gastroenterol2016;3:e000107 PMCID:PMC4964155

[37] Rich NE,Yopp AC,Marrero JA.Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.Aliment Pharmacol Ther2020;52:701-9 PMCID:PMC7655123

[38] Balcar L,Fulgenzi CAM.A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.JHEP Rep2024;6:100982 PMCID:PMC10809085

[39] DelFattore J.Death by stereotype?.N Engl J Med2019;381:982-5

[40] Earle CC,Souza JM,Weeks JC.Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?.J Clin Oncol2008;26:3860-6 PMCID:PMC2654813

[41] Kalff MC,Wagner AD.Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: a population-based study.Eur J Cancer2023;187:114-23

[42] Dijksterhuis WPM,Wagner AD.Gender differences in treatment allocation and survival of advanced gastroesophageal cancer: a population-based study.J Natl Cancer Inst2021;113:1551-60 PMCID:PMC8562959

[43] Wu C,Qian JJ.Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database.Oncotarget2016;7:79442-52 PMCID:PMC5346726

[44] Flores YN,Yang L.Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study.Cancer Epidemiol Biomarkers Prev2021;30:1193-9 PMCID:PMC8172467

[45] Zheng Y,Lu J,Qian Y.Association between socioeconomic status and survival in patients with hepatocellular carcinoma.Cancer Med2021;10:7347-59 PMCID:PMC8525159

[46] Jones PD,Muenyi V,Martin PM.Socioeconomic and survival differences among minorities with hepatocellular carcinoma in Florida.J Hepatocell Carcinoma2019;6:167-81 PMCID:PMC6863179

[47] Karnam RS,Xu W.Sex disparity in liver transplant and access to living donation.JAMA Surg2021;156:1010-7 PMCID:PMC8374729

[48] Locke JE,Olthoff KM.Quantifying sex-based disparities in liver allocation.JAMA Surg2020;155:e201129 PMCID:PMC7240642

[49] Cholongitas E,Kerry A.Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias.Am J Transplant2007;7:685-92

[50] Allen AM,Larson JJ.Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation.Transplantation2018;102:1710-6 PMCID:PMC6153066

[51] Durand F.The quest for equity in liver transplantation: another lesson learned from women.J Hepatol2011;54:401-2

[52] Nephew LD,Lewis JD,Bryan M.Exception points and body size contribute to gender disparity in liver transplantation.Clin Gastroenterol Hepatol2017;15:1286-93.e2 PMCID:PMC10423635

[53] Koh JH,Ng CH.Sex-based disparities in liver transplantation for hepatocellular carcinoma and the impact of the growing burden of NASH.Transplant Direct2024;10:e1642 PMCID:PMC11191941

[54] Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ; Nash HCC Transplant Collaborative. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2024;22:197-9.e3. PMCID:PMC10939135

[55] Kim WR,Heimbach JK.MELD 3.0: the model for end-stage liver disease updated for the modern era.Gastroenterology2021;161:1887-95.e4 PMCID:PMC8608337